RNS Number:6358H
Schering AG
18 February 2003

Autoinjectors improve convenience of Betaferon(R) therapy

Berlin, February 18, 2003 - Schering AG, Berlin (FSE: SCH, NYSE: SHR) today
announced the launch of Betaject(R) Light in Germany as part of the rolling
European programme to make autoinjectors available to patients with multiple
sclerosis. Betaject Light and Betaject(R), the less compact autoinjector for
patients with the advanced form of the disease, are easy to use, automated
mechanical devices that significantly reduce the unwanted side effects of the
injection. Besides Germany, more than fifteen European countries, including
Italy, Spain, Switzerland, Scandinavia and the Netherlands are offering the new
autoinjector technology. Both autoinjectors will also be available in countries
outside the EU.

"Our investment in the autoinjector technology represents our commitment to
enhance the benefits of high-dose, high-frequency Betaferon therapy for the MS
community," said Dr Joachim-Friedrich Kapp, Head of Specialized Therapeutics at
Schering AG. "Betaject and Betaject Light, along with the recently approved
room-temperature stable form of Betaferon, are our latest innovations to reach
more patients and improve the compliance, retention, and length of their
treatment."

According to a study of MS patients using the autoinjector technique instead of
the standard subcutaneous (SC - under the skin) injection method (presented
during the ENS 2002 in Berlin), administration of interferon beta-1b (Betaferon)
with an interferon-free needle using an autoinjector significantly reduced the
occurrence of injection-site reactions by about 60 per cent (p=0.0001). In
addition, almost half of patients (42.8 per cent) using automated self-injection
experienced no injection-site reactions, compared to only 14.3 per cent using
standard SC injection (automated self-injection vs. standard SC injection, 
p=0.001). Overall, automated self-injection resulted in the fewest number of
injection-site reactions (24 per cent of all injections) and appeared to reduce
the risk of severe skin reactions and injection site pain.

"Patients who have long-term experience with interferon beta-1b understand that
initially possible injection site reactions decrease over time," said Carlo
Tornatore, Assistant Professor of Neurology, Georgetown MS Centre, Washington,
D.C., and the lead investigator of the study. "This encouraging study shows
there are steps patients can take to minimize these effects while also
simplifying the injection process."

Commenting on the difference Betaject Light made compared to conventional SC
injection, Allison Carter, an insurance claims negotiator from the United
Kingdom with MS said: "BetajectLight has made my life much better by symplifying
my treatment. It is automatically preset and all you have to do is push the
trigger and the needle automatically goes in at the right speed and depth of
injection. It is much less daunting than regular injections. In addition, I have
no bruising and less injection site reactions. Previously, my husband had to
help administer the medication but now I can do it all myself."

Schering AG is a research-based pharmaceutical company. Its activities are
focused on four business areas: Fertility Control&Hormone Therapy, Diagnostics&
Radiopharmaceuticals, Dermatology as well as Specialized Therapeutics for
disabling diseases in the fields of the central nervous system, oncology and
cardiovascular system. As a global player with innovative products Schering AG
aims for leading positions in specialized markets worldwide. With in-house R&D
and supported by an excellent global network of external partners, Schering AG
is securing a promising product pipeline. Using new ideas, Schering AG aims to
make a recognized contribution to medical progress and strives to improve the
quality of life: making medicine work

This press release has been published by Corporate Communication of Schering AG,
Berlin, Germany.

Your contacts at Corporate Communication:

Business: Dr Friedrich von Heyl, T: +49-30-468 152 96;
friedrich.vonheyl@schering.de

Investor Relations: Peter Vogt, T: +49-30-468 128 38; peter.vogt@schering.de

Pharma: Dr Claudia Schmitt, T: +49-30-468 158 05, claudia.schmitt@schering.de


Your contacts in the US:

Media Relations: Jeanine O'Kane, T:+1-973-487 2095, jeanine_O'kane@berlex.com

Investor Relations: Joanne Marion, T: +1-973-487 2164, joanne_marion@berlex.com

Find additional information at: www.schering.de/eng



Certain statements in this press release that are neither reported financial
results nor other historical information are forward-looking statements,
including but not limited to, statements that are predictions of or indicate
future events, trends, plans or objectives. Undue reliance should not be placed
on such statements because, by their nature, they are subject to known and
unknown risks and uncertainties and can be affected by other factors that could
cause actual results and Schering AG's plans and objectives to differ materially
from those expressed or implied in the forward-looking statements. Certain
factors that may cause such differences are discussed in our Form 20-F and Form
6-K reports filed with the U.S. Securities and Exchange Commission. Schering AG
undertakes no obligation to update publicly or revise any of these
forward-looking statements, whether to reflect new information or future events
or circumstances or otherwise.


                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

PRLFVLFFXLBZBBX